Last Updated: 06/06/2026

Endlyz Therapeutics

London

Founded 2021

Therapeutics targeting lysosomal dysfunction in neurodegeneration

Endlyz Therapeutics is a preclinical-stage biotechnology company developing small molecule modulators to restore endo-lysosomal function in Parkinson's disease and related neurodegenerative conditions.

Its lead programmes target ATP13A2 and ATP10B, lysosomal transporter enzymes linked to neuronal health and Parkinson's disease genetics.

Founded by SV Health Investors' Dementia Discovery Fund, the company is backed by Oxford Science Enterprises, AbbVie Ventures, and Parkinson's UK, with scientific co-founders from the University of Oxford.

Biotech Neurology Drug Discovery

Neurodegenerative Disease Small Molecule Drugs

Is this your company?

Claim this page to receive a verified badge and keep your profile up to date.

Claim page

Company Notes

Member of

BioIndustry Association

Similar Companies